NASDAQ · STOCK
Agilent Technologies
$138.35
52W $108.35 – $160.27
59/100
$39.08B
27.7
1.25
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is A Bullish or Bearish?
Bullish.
Innellis AI committee rates Agilent Technologies (A) Buy with a composite score of 59/100
, based on 6 analysts with 50% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.77 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.23 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 20.8% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.33 across 27 articles, 14d) — News
Bear Case
- P/E of 27.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 15%
of 93 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 20.8% shows genuine earnings power backing the valuation
− P/E of 27.3 is moderate-to-rich
Growth Analyst
bullish
62
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
68
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 27 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 60.1 to 59.2.
- Conviction changed from moderate to contested.
- Committee agreement fell notably from 67% to 50%.
- New bearish signals: 3 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
57.6
Neutral
MACD Histogram
0.258
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$134.29
Resistance
$140.10
Bollinger %B
0.73
Inside Bands
Price vs Moving Averages
EMA 9
$137.80
Above
EMA 21
$135.55
Above
EMA 50
$131.44
Above
EMA 200
$127.97
Above
Fundamental Analysis
Valuation
59
Growth
59
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
27.7×
P/B Ratio
5.50×
PEG Ratio
1.23
Dividend Yield
0.01%
52W High
$160.27
52W Low
$108.35
Quality & Growth
ROE
19.3%
ROA
10.2%
Gross Margin
53.0%
Operating Margin
21.5%
Revenue Growth YoY
—
Debt / Equity
0.47
AI Fundamental Assessment
P/E ratio of 27.7 (moderate relative to a 15-40x range); Price-to-book of 5.5x; PEG ratio of 1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.5%; Current ratio of 2.10 (healthy short-term liquidity); Debt-to-equity of 0.47; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (4.44); Most recent quarter beat estimates by 3.8%; EPS growth accelerating (-14.5% -> +9.6% QoQ); Analyst estimates falling over recent quarters
Get the Full A Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →